Improved primary transplant success rates using a triple regimen of cyclosporine microemulsion, mycophenolate mofetil and prednisone

Khauli, Raja B.; Medawar, Walid; Habbal, A.A; Birbari, A; Daouk, Majida; Abdelnoor, Alexander M.; Uwaydah, Marwan; Bizri, Abdul Rahman; Sanjad, Sami A.; Ayvazian, Philip; Lovewell, Tammy D.; Stoff, Jeffrey S.; Fan, Pengcheng; Bigwood, P; Harland, Robert C.

doi:10.1016/s0041-1345(01)02187-x

Cited by 3 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis of pemphigus was based on (1) typical clinical findings of mucosal or mucocutaneous disease for PV and cutaneous findings for PF; (2) …”

Section: Inclusion Criteriamentioning

confidence: 99%

“…The diagnosis of pemphigus was based on (1) typical clinical findings of mucosal or mucocutaneous disease for PV and cutaneous findings for PF; (2) rect immunofluorescence with IgG as the dominant immunoreactant with or without C3 deposition on epithelial cell surfaces and without any staining at the basement membrane zone; (4) circulating IgG antiepithelial antibodies binding epithelial cell surfaces without recognizing the basement membrane zone, as demonstrated by (a) indirect immunofluorescence with monkey esophagus used as a substrate or (b) antidesmoglein IgG antibodies by enzyme-linked immunosorbent assay; and (5) absence of circulating IgG antibodies binding epithelial cell surface of murine bladder epithelium. Other inclusion criteria were at least 3 months of treatment with a minimum mycophenolate mofetil dosage of 35 mg/kg per day and a minimum follow-up period of 6 months after initiation of mycophenolate therapy.…”

Section: Inclusion Criteriamentioning

confidence: 99%

“…Mycophenolate mofetil is increasingly being used as a corticosteroidsparing agent in immunosuppressive regimens. [2][3][4] Because of its effectiveness and safety profile, mycophenolate has now replaced azathioprine as the antimetabolite adjuvant of choice in the treatment of many autoimmune and inflammatory disorders. 5,6 Recently, there have been several case reports and a small series with short-term follow-up of patients with pemphigus successfully treated with mycophenolate.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus With Mycophenolate Mofetil

Mimouni¹,

Anhalt²,

Cummins³

et al. 2003

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…The diagnosis of pemphigus was based on (1) typical clinical findings of mucosal or mucocutaneous disease for PV and cutaneous findings for PF; (2) …”

Section: Inclusion Criteriamentioning

confidence: 99%

Section: Inclusion Criteriamentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus With Mycophenolate Mofetil

Mimouni¹,

Anhalt²,

Cummins³

et al. 2003

Arch Dermatol

View full text Add to dashboard Cite

show abstract

Bone Quality and Healing in a Swine Vascularized Bone Allotransplantation Model Using Cyclosporine-Based Immunosuppression Therapy

Vossen

Edelstein

Majzoub

et al. 2005

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

Although vascularized bone and joint allotransplantation is a promising new treatment option for reconstructing large bone defects, the need for immunosuppressive agents to prevent rejection in these procedures poses a major problem. This problem stems from the fact that several of these agents can cause harmful side effects, such as alterations in bone quality and healing. Therefore, the purpose of this study was to determine what effect the commonly used immunosuppressant regimen cyclosporine A-based combination therapy has on bone quality and healing. In 10 pigs, vascularized bone allografts with skin and muscle components (osteomyocutaneous free flaps) were transplanted from size-matched donor animals. Recipient animals received oral cyclosporine A/mycophenolate mofetil/prednisone therapy for 90 days. Bone quality was studied before and after transplantation by measuring the bone's acoustic velocity and density and calculating the bone's elastic coefficient. Bone healing was assessed using radiographic analysis. Four animals were lost as a result of graft rejection or immunosuppression-related complications before the 90-day endpoint of the study. Although bone specimens taken from the six animals that completed the 90-day protocol had histological signs of rejection, they all seemed to have normal bone healing. Posttransplant bone density values were significantly decreased (p < 0.05) (1544.7 +/- 47.5 kg/m3) as compared with pretransplant values (1722.7 +/- 44.1 kg/m3). Results of the acoustic velocity and elastic coefficients measurements showed a significant decrease (p < 0.05) in posttransplant values (from 3503.0 +/- 165.1 meters/sec to 2963.0 +/- 54.6 meters/sec and from 21.6 +/- 2.2 GPa to 13.6 +/- 0.5 GPa, respectively), indicating diminished bone quality. The findings indicate that cyclosporine A/mycophenolate mofetil/prednisone combination therapy is ineffective in preventing bone rejection, that it decreases bone quality, and that it is associated with systemic toxicity, suggesting that this immunosuppressive regimen at the doses used in this study is not ideal for vascularized bone allotransplantation procedures.

show abstract

Mycophenolate Mofetil

Young¹,

Plosker²

2002

PharmacoEconomics

View full text Add to dashboard Cite

Pharmacoeconomic studies support the use of mycophenolate mofetil as part of immunosuppressant therapy in renal transplantation, at least in the short term. Although the cost effectiveness of mycophenolate mofetil in the long term is less clear, limited pharmacoeconomic data available appear promising. Among issues to be examined in future economic analyses in renal transplantation are the calcineurin-sparing potential of mycophenolate mofetil and the feasibility of using more efficient mycophenolate mofetil dosage regimens when using the drug on a long-term basis. Additional pharmacoeconomic analyses of mycophenolate mofetil are also needed in other types of solid organ transplantation.

show abstract

Improved primary transplant success rates using a triple regimen of cyclosporine microemulsion, mycophenolate mofetil and prednisone

Cited by 3 publications

References 3 publications

Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus With Mycophenolate Mofetil

Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus With Mycophenolate Mofetil

Bone Quality and Healing in a Swine Vascularized Bone Allotransplantation Model Using Cyclosporine-Based Immunosuppression Therapy

Mycophenolate Mofetil

Contact Info

Product

Resources

About